Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Loxo Oncology CS (LOXO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Loxo Oncology (LOXO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Loxo Oncology, Inc. (LOXO).

LOXO : 132.55 (+2.35%)
Today's Research Reports on Stocks to Watch: Clovis Oncology and Loxo Oncology

NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Clovis Oncology saw its shares close down over 10% on Monday after announcing that it has commenced two separate underwritten public offerings. Shares of Loxo...

MS : 52.04 (-1.94%)
CLVS : 45.10 (-2.51%)
LOXO : 132.55 (+2.35%)
Sorrento Therape has the Best Relative Performance in the Biotechnology Industry (SRNE, LOXO , MDXG , TSRO , ALKS )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

SRNE : 6.10 (+0.83%)
MDXG : 8.24 (+10.90%)
LOXO : 132.55 (+2.35%)
SmarTrend Watching for Potential Pullback in Shares of Loxo Oncology In After 8.19% Gain

Loxo Oncology In (NASDAQ:LOXO) traded in a range yesterday that spanned from a low of $125.25 to a high of $133.95. Yesterday, the shares gained 8.2%, which took the trading range above the 3-day high...

LOXO : 132.55 (+2.35%)
Veracyte Announces Precision Medicine Collaboration With Loxo Oncology

Veracyte, Inc. (Nasdaq: VCYT) today announced a research collaboration through which Loxo Oncology will access Veracyte's new Afirma(R) Xpression Atlas platform to advance its development...

VCYT : 6.13 (-2.54%)
LOXO : 132.55 (+2.35%)
Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

- Expands Illumina's Oncology Offerings for NextSeq(TM) 550Dx with a Companion Diagnostic Version of TruSight(TM) Tumor 170 for Solid Tumors -

ILMN : 231.19 (-3.06%)
LOXO : 132.55 (+2.35%)
Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

--Loxo Oncology to utilize a companion diagnostic version of TruSight Tumor 170 for larotrectinib (NTRK) and LOXO-292 (RET)

ILMN : 231.19 (-3.06%)
LOXO : 132.55 (+2.35%)
Today's Research Reports on Stocks to Watch: Loxo Oncology and Boston Scientific

NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Shares of Loxo Oncology were gaining heavily in Wednesday trading after the company announced that it would be presenting interim results of its Phase 1 clinical...

BSX : 29.42 (+3.23%)
LOXO : 132.55 (+2.35%)
Look for Shares of Loxo Oncology In to Potentially Pullback after Yesterday's 9.07% Rise

Loxo Oncology In (NASDAQ:LOXO) traded in a range yesterday that spanned from a low of $108.75 to a high of $121.70. Yesterday, the shares gained 9.1%, which took the trading range above the 3-day high...

LOXO : 132.55 (+2.35%)
Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that interim clinical...

LOXO : 132.55 (+2.35%)
Blog Exposure - Loxo Oncology Completed Rolling Submission of NDA to the FDA for Larotrectinib for TRK Fusion Cancer Treatment

Stock Monitor: CytRx Post Earnings Reporting

LOXO : 132.55 (+2.35%)
Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancer

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company has...

LOXO : 132.55 (+2.35%)
Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer

WHIPPANY, N.J. , March 26, 2018 /PRNewswire/ -- Bayer today announced that its collaboration partner Loxo Oncology, Inc., (NASDAQ: LOXO) has completed the rolling submission of a New Drug Application...

LOXO : 132.55 (+2.35%)
Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer

Bayer today announced that its collaboration partner Loxo Oncology, Inc., (NASDAQ: LOXO) has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)...

LOXO : 132.55 (+2.35%)
Shares of LOXO Up 25.0% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Loxo Oncology In (NASDAQ:LOXO) on February 13th, 2018 at $97.55. In approximately 1 month, Loxo Oncology In has returned 25.02% as of today's recent price of $121.96....

LOXO : 132.55 (+2.35%)
Today's Research Reports on Trending Tickers: AnaptysBio and Loxo Oncology

NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Stock markets rallied Tuesday on gains from the energy and consumer discretionary sector. Wall Street appears to be eagerly awaiting details from the Federal...

ANAB : 85.35 (-1.92%)
LOXO : 132.55 (+2.35%)
CME : 161.08 (-0.32%)
Loxo Oncology In Shares Up 36.5% Since SmarTrend's Buy Recommendation (LOXO)

SmarTrend identified an Uptrend for Loxo Oncology In (NASDAQ:LOXO) on February 13th, 2018 at $97.55. In approximately 3 weeks, Loxo Oncology In has returned 36.51% as of today's recent price of $133.16....

LOXO : 132.55 (+2.35%)
Loxo Oncology to Present at the Cowen and Company 38th Annual Health Care Conference

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker,...

LOXO : 132.55 (+2.35%)
Look for Shares of Loxo Oncology In to Potentially Pullback after Yesterday's 3.91% Rise

Loxo Oncology In (NASDAQ:LOXO) traded in a range yesterday that spanned from a low of $120.00 to a high of $126.75. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high...

LOXO : 132.55 (+2.35%)
Look for Shares of Loxo Oncology In to Potentially Pullback after Yesterday's 4.74% Rise

Loxo Oncology In (NASDAQ:LOXO) traded in a range yesterday that spanned from a low of $106.52 to a high of $116.49. Yesterday, the shares gained 4.7%, which took the trading range above the 3-day high...

LOXO : 132.55 (+2.35%)

Van Meerten Stock Picks

5 Great Mid Caps
This morning I wanted to find the Mid Cap stocks that not only had some of the best returns in the past 12 months but still seemed to have some upside potential.
IBKR -0.76 , HFC -0.76 , ABMD +2.27 , CAR +0.46 , URBN +0.92
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures ended the Wednesday session with most contracts 5 to 6 cents higher, following wheat. Wednesday’s weekly EIA report showed ethanol production for the week that ended 4/20 dropping 24,000 barrels per day to 985,000 bpd. That is the ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar